Business Description
![Sonnet BioTherapeutics Holdings Inc Sonnet BioTherapeutics Holdings Inc logo](https://static.gurufocus.com/logos/0C0000BTTM.png?14)
Sonnet BioTherapeutics Holdings Inc
NAICS : 541714
SIC : 8731
ISIN : US83548R3030
Share Class Description:
FRA:H3D: Ordinary SharesDescription
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 22.54 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -29.93 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 68.2 | |||||
3-Year EPS without NRI Growth Rate | 78.9 | |||||
3-Year FCF Growth Rate | 65.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 44.01 | |||||
14-Day RSI | 43.26 | |||||
6-1 Month Momentum % | -6.11 | |||||
12-1 Month Momentum % | -71.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.89 | |||||
Quick Ratio | 1.89 | |||||
Cash Ratio | 1.37 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -232.1 | |||||
Shareholder Yield % | -203.7 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -13616.13 | |||||
Net Margin % | -9062.37 | |||||
FCF Margin % | -14113.95 | |||||
ROE % | -297.03 | |||||
ROA % | -105.29 | |||||
ROIC % | -639.87 | |||||
ROC (Joel Greenblatt) % | -5588.26 | |||||
ROCE % | -426.71 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 16.3 | |||||
PB Ratio | 0.9 | |||||
Price-to-Tangible-Book | 0.9 | |||||
EV-to-EBIT | 0.07 | |||||
EV-to-EBITDA | 0.07 | |||||
EV-to-Revenue | -9.44 | |||||
EV-to-FCF | 0.07 | |||||
Price-to-Net-Current-Asset-Value | 1.16 | |||||
Price-to-Net-Cash | 2.93 | |||||
Earnings Yield (Greenblatt) % | 1428.57 | |||||
FCF Yield % | -478.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sonnet BioTherapeutics Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.086 | ||
EPS (TTM) (€) | -4.608 | ||
Beta | 0 | ||
Volatility % | 148.59 | ||
14-Day RSI | 43.26 | ||
14-Day ATR (€) | 0.00009 | ||
20-Day SMA (€) | 5.412 | ||
12-1 Month Momentum % | -71.4 | ||
52-Week Range (€) | 3.475999 - 21.669999 | ||
Shares Outstanding (Mil) | 3.07 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sonnet BioTherapeutics Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Sonnet BioTherapeutics Holdings Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Sonnet BioTherapeutics Holdings Inc Frequently Asked Questions
What is Sonnet BioTherapeutics Holdings Inc(FRA:H3D)'s stock price today?
The current price of FRA:H3D is €5.41. The 52 week high of FRA:H3D is €21.67 and 52 week low is €3.48.
When is next earnings date of Sonnet BioTherapeutics Holdings Inc(FRA:H3D)?
The next earnings date of Sonnet BioTherapeutics Holdings Inc(FRA:H3D) is 2024-08-14 Est..
Does Sonnet BioTherapeutics Holdings Inc(FRA:H3D) pay dividends? If so, how much?
Sonnet BioTherapeutics Holdings Inc(FRA:H3D) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |